Oxford University spin-out applying high-resolution native mass spectrometry through its OdyssION platform to drug membrane proteins and intracellular complexes that have historically been undruggable, with small-molecule programs in orphan endocrine and immunological disease.
$310M Series C financing to advance endocrinology and immunology pipeline toward the clinic
OMass Therapeutics raised a $310 million Series C to push its small-molecule pipeline in endocrinology and immunology toward the clinic, part of a stated ambition to become 'Britain's Big Biotech.'
Chief Executive Officer